Celldex Therapeutics, Inc.
119 Fourth Avenue
Needham,
MA 02494-2725
United States - Map
Phone: 781-433-0771
Fax: 781-433-0262
Web Site: http://www.celldextherapeutics.com
| Celldex Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of vaccines and targeted immunotherapeutics for the treatment of cancer, infectious, and inflammatory diseases. The company focuses on the use of tumor-specific targets and human monoclonal antibodies to precisely deliver therapeutic agents through targeted immunization approach. It also offers bacterial vector delivery technologies with manufacturing and preservation processes that offer the potential for a new generation of infectious disease vaccines. The companys products include Rotarix for the prevention of rotavirus infection; and two human food safety vaccines for reducing salmonella infection in chickens and eggs. Its product pipeline also consists of products in various stages of development, including CDX-110, which is undergoing evaluation in a Phase 2/3 clinical trial for the treatment of glioblastoma multiforme, an aggressive form of brain cancer; CDX-1307, a product based on its proprietary APC Targeting Technology, which is in two Phase 1 clinical trials for patients with advanced pancreatic, bladder, breast, and colon cancer; a TP10, a complement inhibitor for transplantation and other indications; and three candidates based on its oral, rapidly-protecting, single-dose, and temperature-stable vaccine technology, such as combination vaccines for travelers, the military, and health needs. AVANT Immunotherapeutics has collaborative agreements with GlaxoSmithKline for the development and commercialization of oral rotavirus vaccine; Pfizer, Inc. for discovery and development of vaccines to protect animals, and to develop CDX-110; and Select Vaccines Limited for the development of viral vaccines. The company, formerly known as AVANT Immunotherapeutics, Inc., was founded in 1983 and is headquartered in Needham, Massachusetts. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Anthony S. Marucci , 48
Chief Exec. Officer, Pres |
$
440.00K |
$
0 | Mr. Avery W. Catlin , 61
Chief Financial Officer, Sr. VP and Sec. |
$
319.00K |
$
0 | Dr. Tibor Keller Ph.D., 51
Chief Scientific Officer and Sr. VP |
$
346.00K |
$
0 | Dr. Thomas Davis M.D., 46
Chief Medical Officer and Sr. VP |
$
396.00K |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.31% Nasdaq 
0.05%
Profile
